Abstract
Invasive lobular carcinoma (ILC) accounts for 8–14% of all breast cancers and carries distinct prognostic and biologic implications. The goal of our study was to investigate the impact of lobular histology on axillary lymph node (ALN) involvement. This is a cross-sectional study of 4,292 consecutive patients surgically treated for breast carcinoma at the University Hospitals Leuven. Logistic regression analysis was used to relate ILC to lymph node involvement while controlling for the following clinicopathologic features: tumor size, multifocal disease, tumor grade, lobular subtype and the combined steroid, and Her-2 status. Odds ratios (ORs) and 95% confidence intervals (CIS) were computed. A subgroup analysis was performed for patients that underwent a sentinel lymph node (SLN) procedure. The observed incidence of ILC was 13%. ILCs were larger, were more often grade II, multifocal, steroid receptor positive and Her-2 negative, and tended to be present in older patients. Incidence of ALN involvement was 42.0% for ILCs versus 38.3% for other tumors (OR 1.17, 95% CI 0.97–1.40). For the SLN subgroup, ILCs were less often ALN positive than non-ILCs (20.5% versus 28.3%, OR 0.66, 95% CI: 0.41–1.00). In the multivariable analysis, the lobular subtype was identified as less likely to have ALN involvement (adjusted OR 0.66, 95% CI 0.53–0.82). The analysis for the SLN subgroup showed comparable results (adjusted OR 0.49, 95% CI 0.30–0.78). This study has demonstrated that the lobular subtype is an independent predictor of lymph node involvement with ILC having a lower incidence of involved lymph nodes. The mildly higher incidence of ALN metastasis in lobular cancers in univariable analysis is not due to the lobular subtype, but due to confounding factors that interact with lymph node involvement.
Similar content being viewed by others
References
Patani NR, Dwek MV, Douek M (2007) Predictors of axillary lymph node metastasis in breast cancer: a systematic review. Eur J Surg Oncol 33(4):409–419
Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–R156
Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA et al (2005) Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23(1):41–48
Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thurlimann B et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26(18):3006–3014
Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere JM, Bouita L, Cohen-Solal C, Cherel P, Rouesse J (2006) Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 17(8):1228–1233
Viale G, Zurrida S, Maiorano E, Mazzarol G, Pruneri G, Paganelli G, Maisonneuve P, Veronesi U (2005) Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer 103(3):492–500
Wasif N, Maggard MA, Ko CY, Giuliano AE (2010) Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 17(7):1862–1869
Neven P, Van Calster B, Van den Bempt I, Van Huffel S, Van Belle V, Hendrickx W, Decock J, Wildiers H, Paridaens R, Amant F et al (2008) Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. Breast Cancer Res Treat 110(1):153–159
Hastie T, Tibshirani R (1990) Generalized additive models, 1st edn. Chapman and Hall, London; New York
Tubiana M (1998) Benefits and limitations of mass screening. The natural history of breast cancer. Bull Acad Natl Med 182(8):1593–1610 discussion 1610-1591
Bevilacqua JL, Kattan MW, Fey JV, Cody HS III, Borgen PI, Van Zee KJ (2007) Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol 25(24):3670–3679
Voogd AC, Repelaer van Driel OJ, Roumen RM, Crommelin MA, van Beek MW, Coebergh JW (1997) Changing attitudes towards breast-conserving treatment of early breast cancer in the south-eastern Netherlands: results of a survey among surgeons and a registry-based analysis of patterns of care. Eur J Surg Oncol 23(2):134–138
Gann PH, Colilla SA, Gapstur SM, Winchester DJ, Winchester DP (1999) Factors associated with axillary lymph node metastasis from breast carcinoma: descriptive and predictive analyses. Cancer 86(8):1511–1519
Olivotto IA, Jackson JS, Mates D, Andersen S, Davidson W, Bryce CJ, Ragaz J (1998) Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer 83(5):948–955
Velanovich V, Szymanski W (1998) Lymph node metastasis in breast cancer: common prognostic markers lack predictive value. Ann Surg Oncol 5(7):613–619
Voogd AC, Coebergh JW, Repelaer van Driel OJ, Roumen RM, van Beek MW, Vreugdenhil A, Crommelin MA (2000) The risk of nodal metastases in breast cancer patients with clinically negative lymph nodes: a population-based analysis. Breast Cancer Res Treat 62(1):63–69
Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart P (1996) Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77(1):113–120
Cserni G (2006) Histopathologic examination of the sentinel lymph nodes. Breast J 12(5 Suppl 2):S152–S156
Patil DT, Susnik B (2008) Keratin immunohistochemistry does not contribute to correct lymph node staging in patients with invasive lobular carcinoma. Hum Pathol 39(7):1011–1017
Maiorano E, Regan MM, Viale G, Mastropasqua MG, Colleoni M, Castiglione-Gertsch M, Price KN, Gelber RD, Goldhirsch A, Coates AS (2010) Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat 121(1):211–218
Zurrida S, Morabito A, Galimberti V, Luini A, Greco M, Bartoli C, Raselli R, Rossi N, Vessecchia G, Cascinelli N et al (1999) Importance of the level of axillary involvement in relation to traditional variables in the prognosis of breast cancer. Int J Oncol 15(3):475–480
Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, Clarke C, Lakhani SR, Simpson PT (2008) Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 32(5):773–783
Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO (2005) E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 46(6):685–693
Michaelson JS, Silverstein M, Wyatt J, Weber G, Moore R, Halpern E, Kopans DB, Hughes K (2002) Predicting the survival of patients with breast carcinoma using tumor size. Cancer 95(4):713–723
Verkooijen HM, Fioretta G, Vlastos G, Morabia A, Schubert H, Sappino AP, Pelte MF, Schafer P, Kurtz J, Bouchardy C (2003) Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 104(6):778–781
Dixon AR, Ellis IO, Elston CW, Blamey RW (1991) A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer 63(4):634–635
Gudlaugsson E, Skaland I, Janssen EA, van Diest PJ, Voorhorst FJ, Kjellevold K, zur Hausen A, Baak JP (2010) Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer. Breast Cancer Res Treat 121(1):35–40
Toikkanen S, Pylkkanen L, Joensuu H (1997) Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 6(9):1234–1240
Acknowledgments
BVC is a postdoctoral fellow of the Research Foundation—Flanders (FWO). KVH is supported by a grant from the Agency for Innovation by Science and Technology (IWT).
Author information
Authors and Affiliations
Corresponding author
Additional information
T. Vandorpe and A. Smeets contributed equally in this study.
Rights and permissions
About this article
Cite this article
Vandorpe, T., Smeets, A., Van Calster, B. et al. Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients. Breast Cancer Res Treat 128, 429–435 (2011). https://doi.org/10.1007/s10549-011-1565-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-011-1565-4